Find in Library

Background: Traditional usage (typhoid, diarrhea, sore throat) and previously performed studies (antioxidative and anticancer activity) have asserted that Eurya acuminata has a widespread therapeutic potential. However, most of the pharmacological aspects of this plant are yet to be explored.Methods: Broth dilution method was selected to determine the minimum inhibitory concentration (MIC) of the plant extract. Antidiarrheal activity was figured out following the castor oil-induced diarrheal inhibition method. The oral glucose tolerance test (OGTT) was performed to assess antihyperglycemic activity. Alpha-glucosidase inhibitory assay was conducted according to the supplier's method. Acetic acid-induced writhing inhibition method was used to evaluate the peripheral analgesic activity.Results: HPLC analysis detected the presence of (-)-epicatechin, p-coumaric acid, trans-ferulic acid, rosmarinic acid, myricetin, and trans-cinnamic acid. In the broth dilution method, the extract exhibited MIC of 16 μg/ml against E. coli and S. aureus and 8 μg/ml against P. aeruginosa. In castor oil-induced antidiarrheal assay, E. acuminata extract significantly reduced 44.82% and 67.24% defecation, respectively at the doses of 250 and 500 mg/kg. Furthermore, in in vivo antihyperglycemic activity, E. acuminata extract reduced blood glucose levels to 6.8 mM and 4.68 mM, at the doses of 250 and 500 mg/kg, respectively at 60 min although the extract demonstrated no α-glucosidase enzyme inhibitory activity. Apart from that, in in vivo analgesic activity, the extract inhibited writhing reflexes dose-dependently, 15.16% and 37.13% at the doses of 250 and 500 mg/kg.Conclusion: This study shows that E. acuminata might be a good source to explore antidiarrheal, antihyperglycemic, and antimicrobial compounds for new drug development.